Psoriasis Treatment Options: From Topicals to Systemic Therapy

Psoriasis treatment has changed substantially in the last two decades, and a lot of people's understanding of their options is still based on what was available years ago, primarily topical steroids and light therapy. The treatment ladder now extends considerably further, and matching the treatment to disease severity, rather than staying on topicals longer than necessary, makes a real difference in outcomes.

Psoriasis is not only a skin condition

Psoriasis is a systemic autoimmune condition driven by immune system overactivity, not simply dry or irritated skin. This distinction matters clinically: psoriasis is associated with increased risk of psoriatic arthritis (affecting up to 30 percent of people with psoriasis), cardiovascular disease, and metabolic syndrome. Treating psoriasis as purely a cosmetic skin issue misses this broader picture, and screening for joint symptoms specifically is a standard part of psoriasis care.

Mild disease: topical treatment

For limited psoriasis, topical corticosteroids remain first-line, often combined with vitamin D analogs (like calcipotriene), which work through a different mechanism and allow for lower steroid potency when combined. This combination approach is more effective than either alone for many patients with mild, localized disease.

Moderate disease: phototherapy and beyond

When psoriasis covers a larger area or does not respond adequately to topical treatment, phototherapy (controlled UV light exposure, typically narrowband UVB) is a well-established option with a strong safety record, though it requires a real time commitment, typically two to three sessions per week.

When systemic treatment becomes appropriate

There is no single percentage cutoff that mandates systemic treatment, but psoriasis covering more than roughly 5 to 10 percent of body surface area, or significantly affecting sensitive areas like the face, hands, scalp, or genitals, or psoriasis that has not responded adequately to topical treatment and phototherapy, are the general indicators that it is time to move beyond topical-only management.

Oral systemic medications (methotrexate, apremilast, and others) work through different immune-modulating mechanisms and have been used for psoriasis for decades, each with its own monitoring requirements.

Biologic medications: the more recent shift

Biologic medications, which target specific components of the immune pathway driving psoriasis (such as TNF-alpha, IL-17, or IL-23), represent the most significant advance in psoriasis treatment in the last 20 years. For many patients with moderate to severe psoriasis, biologics achieve complete or near-complete skin clearance, a level of response that was uncommon with older treatments. They require periodic monitoring, primarily around infection risk, but have a substantial safety track record at this point, with multiple options approved and in wide use.

Building the right treatment plan

Moving through this ladder appropriately, not staying on topical treatment indefinitely once it is clearly insufficient, matters both for skin outcomes and because psoriasis severity correlates with the broader systemic risks it carries. If you have psoriasis that is not well controlled by your current treatment, or joint symptoms that have not been evaluated, that is worth raising directly. Most major insurance plans, including Medicare, cover the dermatology evaluation and treatment escalation this requires.